



Tuesday, December 11, 2007 - 10:51 AM EST

Organogenesis inks Asian market deal with Chinese group

Mass High Tech: The Journal of New England Technology

A Canton biotech has struck a deal with a Chinese stem cell company.

Organogenesis Inc. has signed a memorandum of understanding with China's National Tissue Engineering Center, a stem cell and regenerative medicine consortium, headquartered in Shanghai, according to officials.

The Canton-based regenerative medicine company formed the three-phase agreement with the NTEC this past week, while visiting China as a delegate of Gov. Deval Patrick's trade mission.

According to the agreement, the first phase of the partnership would commence immediately, and include the commercializing and exporting existing Organogenesis Inc. technology -- including its signature product, Apligraf -- in China, and eventually throughout Asia.

Phase two includes manufacturing existing Organogenesis cell therapies in Shanghai. Phase three includes the co-development of new technologies, which may be custom-designed for Chinese market needs. Organogenesis would hold the commercial rights for all Western markets for new technology developed.

The NTEC is a government-funded private company. Its founder, Yiling Cao, is a plastic surgeon who was trained at Harvard University and MIT, where Organogenesis was founded.